FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain:
- the ins and outs of lay summary writing,
- the importance of starting a pilot program,
- a checklist for lay reviewers, and
- strategic advice for becoming more transparent.
Click on the image for the full whitepaper.
This whitepaper was authored by Manager of Disclosures Services Kasim McLain, Senior Transparency Lead and Medical Writer Jennifer Pilgrim, and Associate Manager of Corporate Quality Jessica Alamdari.
Suggested For You
perspectives
July 8th, 2025
Guidance for Working with External Data Vendors – Getting from LPLV to Database Lock Faster
perspectives
July 1st, 2025
Why Real-Time Data Access Matters (and How to Make the Most of It)
perspectives
June 24th, 2025
Why Now Is the Time for Specialized, Data-Focused CRO Partners
perspectives
June 17th, 2025
Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise
perspectives
June 10th, 2025
Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives
perspectives
June 3rd, 2025
Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs